Search Results for: covid-19
Articles
Positive Phase 2 Data of Novel Investigational Anti-CD40L Antibody Frexalimab Show Significantly Reduced Disease Activity in Relapsing Multiple Sclerosis May 31, 2023
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate...MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy May 30, 2023
MetrioPharm AG recently announced the US FDA has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular...SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development? May 1, 2023
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs May 1, 2023
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
DELIVERY DEVICES - Growing Connected Market Set to Elevate Healthcare Outcomes May 1, 2023
Michael Earl examines what the connected device market will look to achieve in the coming years and how it is likely to drive improved adherence to treatments and improve overall healthcare outcomes.
Soligenix Enters Exclusive Option Agreement With Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease May 1, 2023
Soligenix, Inc. recently announced it has entered into an exclusive option agreement with Silk Road Therapeutics granting the company the...Aptamers Market is Expected to Reach $342 million April 27, 2023
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the...Dyadic Announces Expanded Licensing Agreement to Develop & Commercialize Vaccines & Biologics for African Continent April 12, 2023
Dyadic International, Inc. recently announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s...SPECIAL FEATURE - Excipients: Their Future Could Lie in Generics April 3, 2023
Contributor Cindy H. Dubin highlights the innovative work being done by several leading companies and exemplifies the importance of excipients to the future of drug development.
MARKET TRENDS - The Year of Resilience & Flexibility: Six Smart Ways CDMOs Are Preparing for 2023 April 3, 2023
Carsten Press says with biopharma businesses weathering one unexpected shift after another, it’s no surprise these organizations are looking to their partner networks for one thing above all: the flexibility they need to maximize their own business resilience.
EXECUTIVE INTERVIEW - ICON: Transforming Clinical Trials in a Rapidly Shifting Landscape April 3, 2023
Ute Berger, MD, President, Development & Commercialization Solutions at ICON plc, discusses how with the acquisition of PRA in 2021, it has enhanced its value proposition and how it is transforming clinical trials in a rapidly shifting landscape.
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases April 3, 2023
HCW Biologics Inc. recently published a pivotal scientific paper in Aging Cell titled Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice with Dr. Hing C. Wong, the company’s Founder and CEO, as lead and….
WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives March 31, 2023
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma...Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder March 28, 2023
Revive Therapeutics Ltd. recently provided an update on the company’s Phase 1/2 clinical study (NCT05322954) evaluating the safety and feasibility...Vaccitech Announces Positive Topline Final Data for HBV002 Study in People With Chronic Hepatitis B March 28, 2023
Vaccitech plc recently announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300...Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program March 23, 2023
Arch Biopartners Inc. recently announced it is receiving advisory services and up to $4 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the….
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia March 20, 2023
Vaxxinity, Inc. recently announced the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein….
Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany March 8, 2023
Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….
MARKET TRENDS - Emerging Trends in Injectable Drug Formulation & Delivery March 1, 2023
Martin Gonzalez, PhD, details current trends in sterile injectable formulations and delivery devices and highlights the challenges pharma and its CDMO partners are facing bringing emerging parenteral breakthroughs to patients.
SUSTAINABILITY - Is the Pharmaceutical Industry Preparing Effectively for a Greener Future? March 1, 2023
Michael Earl reviews 25 of the biggest pharma companies reporting environmental, social, and governance (ESG) scores to see how the industry is performing.
